It is a molecular test based on microRNAs that analyzes fine needle aspiration biopsy (FNAB) material to determine whether a thyroid nodule classified as Bethesda III or IV has benign or malignant characteristics.

No new puncture is required: it is performed using the same sample already obtained in the FNA.

Key benefits

• Avoid unnecessary surgeries: reduce avoidable surgical procedures by up to 75%.
• High diagnostic accuracy: negative predictive value of 96% and positive predictive value of 76%.
• Based on international clinical evidence and recommended by guidelines from the American Thyroid Association (ATA) and NCCN.
• Supports surgical planning: identifies markers associated with aggressive tumors, optimizing therapeutic decision-making.

Molecular markers analyzed

• miR-375: associated with medullary carcinoma.
• miR-146b: associated with risk of papillary carcinoma.
• BRAF V600E and TERT C228T/C250T: mutations linked to increased tumor aggressiveness.

Molecular markers analyzed

• miR-375: associated with medullary carcinoma.
• miR-146b: associated with risk of papillary carcinoma.
• BRAF V600E and TERT C228T/C250T: mutations linked to increased tumor aggressiveness.